These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 2602422)
1. Neuronal loss in the substantia nigra in patients with Alzheimer's disease and Parkinson's disease in relation to extrapyramidal symptoms and dementia. Rinne JO; Rummukainen J; Paljärvi L; Säkö E; Mölsä P; Rinne UK Prog Clin Biol Res; 1989; 317():325-32. PubMed ID: 2602422 [TBL] [Abstract][Full Text] [Related]
2. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Rinne JO; Rummukainen J; Paljärvi L; Rinne UK Ann Neurol; 1989 Jul; 26(1):47-50. PubMed ID: 2549846 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical study of the striatal efferents and nigral dopaminergic neurons in parkinsonism-dementia complex on Guam in comparison with those in Parkinson's and Alzheimer's diseases. Goto S; Hirano A; Matsumoto S Ann Neurol; 1990 May; 27(5):520-7. PubMed ID: 1694418 [TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study. Jellinger KA Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452 [TBL] [Abstract][Full Text] [Related]
5. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230 [TBL] [Abstract][Full Text] [Related]
6. Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease. de la Monte SM; Wells SE; Hedley-Whyte T; Growdon JH Ann Neurol; 1989 Sep; 26(3):309-20. PubMed ID: 2802531 [TBL] [Abstract][Full Text] [Related]
7. Neuropathological substrates of Alzheimer's disease and Parkinson's disease. Jellinger K J Neural Transm Suppl; 1987; 24():109-29. PubMed ID: 3316494 [TBL] [Abstract][Full Text] [Related]
8. Dendritic reorganisation in the basal forebrain under degenerative conditions and its defects in Alzheimer's disease. III. The basal forebrain compared with other subcortical areas. Arendt T; Brückner MK; Bigl V; Marcova L J Comp Neurol; 1995 Jan; 351(2):223-46. PubMed ID: 7699112 [TBL] [Abstract][Full Text] [Related]
9. Pathological correlates of extrapyramidal signs in Alzheimer's disease. Liu Y; Stern Y; Chun MR; Jacobs DM; Yau P; Goldman JE Ann Neurol; 1997 Mar; 41(3):368-74. PubMed ID: 9066358 [TBL] [Abstract][Full Text] [Related]
10. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. Chan-Palay V J Comp Neurol; 1988 Jul; 273(4):543-57. PubMed ID: 2463283 [TBL] [Abstract][Full Text] [Related]
11. The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs. Burns JM; Galvin JE; Roe CM; Morris JC; McKeel DW Neurology; 2005 Apr; 64(8):1397-403. PubMed ID: 15851730 [TBL] [Abstract][Full Text] [Related]
13. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Burton EJ; McKeith IG; Burn DJ; Williams ED; O'Brien JT Brain; 2004 Apr; 127(Pt 4):791-800. PubMed ID: 14749292 [TBL] [Abstract][Full Text] [Related]
14. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211 [TBL] [Abstract][Full Text] [Related]
15. A pathological study of the association between Lewy body disease and Alzheimer's disease. Gibb WR; Mann DM; Mountjoy CQ; Lees AJ Adv Neurol; 1990; 53():55-9. PubMed ID: 2173375 [No Abstract] [Full Text] [Related]
16. [A 78-year-old man with young onset parkinsonism and sudden death]. Miyasaka H; Mori H; Saikawa T; Shirai T; Kondo T; Imai H; Mizuno Y No To Shinkei; 1996 May; 48(5):487-95. PubMed ID: 8672309 [TBL] [Abstract][Full Text] [Related]
17. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Novikova L; Garris BL; Garris DR; Lau YS Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572 [TBL] [Abstract][Full Text] [Related]
18. The pedunculopontine nucleus in Parkinson's disease. Zweig RM; Jankel WR; Hedreen JC; Mayeux R; Price DL Ann Neurol; 1989 Jul; 26(1):41-6. PubMed ID: 2549845 [TBL] [Abstract][Full Text] [Related]
19. Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease? Papapetropoulos S; Lieberman A; Gonzalez J; Mash DC Acta Neurol Scand; 2005 Jun; 111(6):353-9. PubMed ID: 15876335 [TBL] [Abstract][Full Text] [Related]